Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics (Nasdaq: FULC) granted inducement non‑statutory stock options to three new employees under its 2022 Inducement Stock Incentive Plan in reliance on Nasdaq Listing Rule 5635(c)(4).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Fulcrum Therapeutics (Nasdaq: FULC) granted inducement non‑statutory stock options to three new employees under its 2022 Inducement Stock Incentive Plan in reliance on Nasdaq Listing Rule 5635(c)(4).
The company granted a total of 30,400 options at an exercise price of $10.84 per share, equal to the closing price on the grant effective date, January 5, 2026. Each option has a 10‑year term and vests over four years: 25% on the first anniversary of employment, then 6.25% quarterly for the following twelve quarters, subject to continued service.
Details
News Market Reaction – FULC
On Jan 12, the first trading day after this news, FULC closed 3.45% below the previous close.
Data tracked by StockTitan Argus for the Jan 12 session.
Key Figures
- Inducement options
- 30,400 options
- Granted to three new employees under 2022 Inducement Plan
- Exercise price
- $10.84 per share
- Closing price on grant effective date January 5, 2026
- Option term
- 10 years
- Non-statutory stock options granted under inducement plan
- Vesting schedule
- 4 years
- 25% at first anniversary, then 6.25% quarterly over 12 quarters
- New employees
- 3 employees
- Recipients of inducement stock option grants
Historical Context
-
Announcement of presentation at the 44th J.P. Morgan Healthcare Conference.
-
Pricing of upsized $175M common stock and pre-funded warrant offering.
-
Proposed $150M common stock offering under effective shelf registration.
-
Positive initial results from 20 mg Phase 1b PIONEER cohort in sickle cell.
-
Inducement stock options granted to a new hire under the 2022 Plan.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
non-statutory stock options financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to three new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).
Fulcrum granted the new employees 30,400 options to purchase shares of the company’s common stock at an exercise price of
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit http://www.fulcrumtx.com and follow us on X (@FulcrumTx) and LinkedIn.
Contact:
Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.